

1 **Constitutive G protein coupling profiles of understudied orphan GPCRs**

2

3 Sumin Lu<sup>1</sup>, Wonjo Jang<sup>1</sup>, Asuka Inoue<sup>2</sup> and Nevin A. Lambert<sup>1</sup>

4

5 <sup>1</sup>Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University,  
6 Augusta, GA 30912, USA

7 <sup>2</sup>Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan

8

9 **Correspondence:**

10 Nevin Lambert

11 1460 Laney Walker Boulevard

12 Augusta, Georgia 30912

13 USA

14

15 706-721-6336

16 E-mail: nelambert@augusta.edu.

17

18 **ORCID:**

19 Wonjo Jang: <https://orcid.org/0000-0002-1928-8978>

20 Nevin Lambert: <https://orcid.org/0000-0001-7550-0921>

21

22

23 **Author contributions:** S.L. and W.J. carried out all experimental procedures. A.I. generated  
24 and validated the G protein-deficient cell line. S.L., W.J. and N.L. analyzed and interpreted data.  
25 N.L. prepared figures and drafted the manuscript. All authors reviewed, revised, and approved  
26 the manuscript for publication.

27

28 **Abstract**

29 A large number of GPCRs are potentially valuable drug targets but remain understudied. Many  
30 of these lack well-validated activating ligands and are considered “orphan” receptors, and G  
31 protein coupling profiles have not been defined for many orphan GPCRs. Here we asked if  
32 constitutive receptor activity can be used to determine G protein coupling profiles of orphan  
33 GPCRs. We monitored nucleotide-sensitive interactions between 48 understudied orphan  
34 GPCRs and five G proteins (240 combinations) using bioluminescence resonance energy  
35 transfer (BRET). No receptor ligands were used, but GDP was used as a common G protein  
36 ligand to disrupt receptor-G protein complexes. Constitutive BRET between the same receptors  
37 and  $\beta$ -arrestins was also measured. We found sufficient GDP-sensitive BRET to generate G  
38 protein coupling profiles for 22 of the 48 receptors we studied. Altogether we identified 48  
39 coupled receptor-G protein pairs, many of which have not been described previously. We  
40 conclude that receptor-G protein complexes that form spontaneously in the absence of guanine  
41 nucleotides can be used to profile G protein coupling of constitutively active GPCRs. This  
42 approach may prove useful for studying G protein coupling of other GPCRs for which activating  
43 ligands are not available.

44

## 45 Introduction

46 G protein-coupled receptors (GPCRs) are the targets of a large fraction of clinically-useful  
47 drugs, and efforts to develop new drugs targeting GPCRs are ongoing [1]. Defining  
48 characteristics of GPCRs are the natural ligands that bind and activate each receptor, and the  
49 intracellular transducers (G proteins and arrestins) that propagate signals to downstream  
50 effectors [2]. Individual GPCRs can couple to several different G proteins from more than one G  
51 protein family. Because each of the four G protein families ( $G_{s/olf}$ ,  $G_{i/o}$ ,  $G_{q/11}$ , and  $G_{12/13}$ ) activates  
52 different downstream effectors, GPCR-G protein coupling profiles have traditionally been  
53 determined using second messenger assays, most commonly those that measure intracellular  
54 cyclic AMP (cAMP) and calcium. Although these assays are robust and quite sensitive,  
55 crosstalk between pathways can complicate interpretation, and comparable second messenger  
56 assays are not available for all four families. G protein coupling can also be determined by more  
57 direct methods, such as [ $^{35}$ S]GTP $\gamma$ S binding *in vitro*, but these methods are more difficult to  
58 implement, particularly at scale across multiple G protein subtypes [3]. More recently, genetic,  
59 spectroscopic and luminometric assays have been developed that allow more direct  
60 assessment of G protein coupling profiles in living cells [4–8]. These assays can detect coupling  
61 to all four G protein families, avoid ambiguity due to signal crosstalk, and are efficient enough to  
62 allow profiling of a large number of GPCRs in parallel.

63

64 Several recent studies have used these methods to profile G protein coupling of GPCRs in  
65 response to activating ligands [9–12]. However, for a large number of so-called orphan GPCRs  
66 the natural ligand is either not known or not well-validated, and surrogate activating ligands are  
67 not available [13]. Therefore, studies profiling G protein coupling have generally not included  
68 orphan GPCRs. In a recent study we found that many GPCRs would spontaneously form  
69 complexes with cognate G proteins in the absence of guanine nucleotides, and these  
70 complexes were disrupted by the addition of GDP [14]. This is consistent with the known ability  
71 of constitutively-active GPCRs to activate G proteins in the absence of an agonist [15]. It  
72 occurred to us that the nucleotide-sensitivity of spontaneous GPCR-G protein complexes could  
73 be used to define coupling profiles of orphan GPCRs without using activating ligands. Here we  
74 test this idea using 48 orphan GPCRs, most of which have not been extensively studied or  
75 characterized. We find that approximately half of the receptors we studied possess sufficient  
76 constitutive activity to define a G protein coupling profile. These results may facilitate efforts  
77 aimed at understanding the physiological roles these receptors, and at discovering and  
78 validating new drugs acting at GPCRs.

79

## 80 **Materials and Methods**

81

### 82 **Materials**

83 Trypsin, culture media, PBS, DPBS, penicillin/streptomycin and L-glutamine were from GIBCO  
84 (ThermoFisher Scientific, Waltham, MA, USA). PEI MAX was purchased from Polysciences Inc.  
85 (Warrington, PA, USA). Digitonin, apyrase and GDP were purchased from MilliporeSigma (St.  
86 Louis, MO, USA). Coelenterazine h was purchased from Nanolight Technologies (Pinetop, AZ,  
87 USA).

88

### 89 **Plasmid DNA constructs**

90 GPCR coding sequences were provided by Bryan Roth (University of North Carolina, Chapel  
91 Hill, NC; PRESTO-Tango Kit - #1000000068, Addgene, Watertown), MA, USA) [16], except for  
92 GPR139, which was a gift from Kirill Martemyanov [17]. For each receptor the coding sequence  
93 was amplified with a common forward primer (corresponding to a cleavable signal sequence)  
94 and custom reverse primer (corresponding to the receptor C terminus) and ligated into a  
95 pRluc8-N1 cloning vector. All plasmid constructs were verified by Sanger sequencing. Plasmids  
96 encoding Venus-Kras, Venus-PTP1b, Venus-1-155-G $\gamma$ <sub>1</sub>, and Venus-155-239-G $\beta$ <sub>1</sub> have been  
97 described previously [4,18]. G $\alpha$  subunit plasmids were purchased from cdna.org (Bloomsburg  
98 University, Bloomsburg, PA). Plasmids encoding Venus- $\beta$ -arrestin-1 and -2 were a gift from  
99 Vsevolod Gurevich (Vanderbilt University, Nashville, TN, USA), and plasmids encoding the S1  
100 subunit of pertussis toxin (PTX-S1) was kindly provided by Stephen R. Ikeda (NIAAA, Rockville,  
101 MD, USA).

102

### 103 **Cell culture and transfection**

104 HEK 293 cells (CLS Cat# 300192/p777\_HEK293, RRID:CVCL\_0045; ATCC, Manassas, VA,  
105 USA) were propagated in plastic flasks and on 6-well plates according to the supplier's protocol.  
106 HEK 293 cells with targeted deletion of *GNAS*, *GNAL*, *GNAQ*, *GNA11*, *GNA12* and *GNA13* (G  
107 protein three family knockouts; 3GKO) were derived, authenticated and propagated as  
108 previously described [19]. Cells were transfected in growth medium using linear  
109 polyethyleneimine MAX (PEI MAX; MW 40,000) at an nitrogen/phosphate ratio of 20 and were  
110 used for experiments 48 hours later. Up to 3.0  $\mu$ g of plasmid DNA was transfected in each well  
111 of a 6-well plate. For G protein experiments 3GKO cells were transfected with a GPCR-Rluc8,  
112 G $\alpha$  subunit, Venus-1-155-G $\gamma$ <sub>2</sub>, Venus-155-239-G $\beta$ <sub>1</sub>, and pcDNA3.1(+) or PTX-S1 in a  
113 (1:10:5:5:5) ratio for a total of 2.6  $\mu$ g of plasmid DNA in each well of a 6-well plate. For arrestin

114 experiments HEK 293 cells were transfected with a GPCR-Rluc8, Venus- $\beta$ -arrestin-1 or -2,  
115 GRK2 and GRK6 in a 1:10:5:5 ratio for a total of 2.1  $\mu$ g of plasmid DNA. For trafficking  
116 experiments HEK 293 cells were transfected with a GPCR-Rluc8 and either Venus-Kras or  
117 Venus-PTP1b in a 1:10 ratio for a total of 1.1  $\mu$ g of plasmid DNA.

118

### 119 **BRET assays**

120 For G protein coupling experiments cells were washed twice with permeabilization buffer (KPS)  
121 containing 140 mM KCl, 10 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.1 mM KEGTA, 20 mM NaHEPES (pH  
122 7.2), harvested by trituration, permeabilized in KPS buffer containing 10  $\mu$ g ml<sup>-1</sup> high purity  
123 digitonin, and transferred to opaque black 96-well plates. Measurements were made from  
124 permeabilized cells supplemented either with 100  $\mu$ M GDP or 2U ml<sup>-1</sup> apyrase. For arrestin and  
125 trafficking experiments cells were washed twice in PBS and harvested by trituration in DPBS.  
126 For all experiments 5  $\mu$ M coelenterazine h was used as a substrate. For the experiments shown  
127 in Fig 1, permeabilized cells were supplemented with apyrase, and GDP (100  $\mu$ M) was injected  
128 during continuous recording using a Polarstar Optima plate reader (BMG Labtech, Offenburg,  
129 Germany). All other measurements were made using a Mithras LB940 photon-counting plate  
130 reader (Berthold Technologies GmbH, Bad Wildbad, Germany). Raw BRET signals were  
131 calculated as the emission intensity at 520-545 nm divided by the emission intensity at 475-495  
132 nm. Net BRET signals were calculated as the raw BRET signal minus the raw BRET signal  
133 measured from cells expressing only the Rluc8 donor.

134

### 135 **Statistical analysis**

136 The data shown in Fig 1 represent the mean  $\pm$  SD of 16 technical replicates from one exemplary  
137 experiment. Because background basal BRET differed for each G protein, in this experiment  
138 raw BRET values for each trace are normalized the average of the first ten data points of all of  
139 the traces for a particular G protein. The data shown in Fig 2 represent the average of three  
140 independent experiments, each performed in duplicate. G protein heat maps (Fig 3) represent  
141 the difference in the raw BRET ratios measured from cells incubated in presence and absence  
142 of GDP ( $\Delta$ BRET<sub>GDP</sub>). Arrestin heat maps represent the basal net BRET. No hypothesis testing  
143 was performed and no claims of statistical significance are made. The threshold for assigning G  
144 protein coupling was determined by assuming that the majority of receptor-G protein pairs would  
145 be uncoupled, and that the  $\Delta$ BRET<sub>GDP</sub> values for these pairs would be randomly distributed  
146 around zero. Coupled pairs were detected as outliers from this distribution using the ROUT

147 method [20] implemented in GraphPad Prism 8 (GraphPad Software, La Jolla, CA) with Q (the  
148 maximum false discovery rate) set to 1%, meaning fewer than 1% of the detected (coupled)  
149 pairs are expected to be false-positives. The same procedure was used to detect receptor-  
150 arrestin pairs.

151 **Results**

152

153 **Receptor-G protein interactions**

154 We have previously monitored direct interactions between GPCRs and G proteins using  
155 bioluminescence resonance energy transfer (BRET) between receptors fused to *Renilla*  
156 luciferase (Rluc8) and G protein heterotrimers tagged with the fluorescent protein Venus. Using  
157 permeabilized cells we found that many GPCRs spontaneously interacted with G proteins in a  
158 nucleotide-sensitive fashion [14]. Importantly, these constitutive GDP-sensitive interactions  
159 corresponded well to known G protein coupling, suggesting that it should be possible to study G  
160 protein coupling of orphan GPCRs without using activating ligands. To test this idea we fused  
161 Rluc8 to the C terminus of 48 class A orphan receptors, 43 of which are on the most recent list  
162 of understudied GPCR targets compiled by the Illuminating the Druggable Genome (IDG)  
163 project [21,22]. Receptors were coexpressed together with a  $G\alpha$  subunit and Venus-G $\beta\gamma$  in  
164 genome-edited HEK 293 cells lacking endogenous  $G_{s/olf}$ ,  $G_{q/11}$  and  $G_{12/13}$  proteins [19]. We  
165 chose one  $G\alpha$  subunit to represent each of the four G protein families ( $G\alpha_{i1}$ ,  $G\alpha_s$ -long,  $G\alpha_q$ ,  
166  $G\alpha_{13}$ ) as well as  $G\alpha_{15}$ , due to its unique coupling properties [23]. Except when  $G\alpha_{i1}$  was used,  
167 we also transfected the S1 subunit of pertussis toxin to prevent coupling of endogenous  $G_{i/o}$   
168 proteins to GPCRs.

169

170 Complexes between constitutively-active receptors and cognate G proteins formed  
171 spontaneously in permeabilized cells when apyrase was used to hydrolyze residual guanine  
172 nucleotides, thus maintaining the nucleotide-empty state of the G protein. Addition of GDP (100  
173  $\mu$ M) led to rapid complex dissociation, and a decrease in BRET between receptors and G  
174 proteins (Fig 1A). For example, GPR82 formed GDP-sensitive complexes with  $G_{i1}$  heterotrimers,  
175 but not with  $G_s$ ,  $G_q$ , or  $G_{13}$  heterotrimers (Fig 1B). In contrast, GPR174 formed GDP-sensitive  
176 complexes primarily with  $G_s$  and  $G_{13}$  heterotrimers (Fig 1B). Almost nothing is known about  
177 GPR82 (Jensen PubMed Score 1.16), which is listed as a “probable” GPCR, and we were  
178 unable to find any reports of GPR82 coupling to G proteins in the literature. In contrast, GPR174  
179 (Jensen PubMed Score 10.06) has been described as a receptor for lysophosphatidyl-L-serine  
180 (lysoPS) [7] and the chemokine CCL21 [24], and is known to couple to  $G_{s/olf}$  and  $G_{12/13}$   
181 heterotrimers [9]. These results demonstrate the utility of this approach for profiling G protein  
182 coupling of orphan GPCRs.

183

184 Changes in BRET after addition of GDP ( $\Delta\text{BRET}_{\text{GDP}}$ ) for the 240 pairings in our sample  
185 clustered around zero, as expected if the majority of receptor-G protein pairs do not  
186 constitutively couple (Fig 2). However, a population of more negative values of  $\Delta\text{BRET}_{\text{GDP}}$  was  
187 apparent that presumably corresponds to coupled receptor-G protein pairs. We set a  
188 conservative threshold for coupling by identifying outliers from a random distribution of  
189  $\Delta\text{BRET}_{\text{GDP}}$  values, using a false discovery rate (FDR) of 1% (see Materials and Methods).

190  
191 Using this threshold G protein coupling was detected for 22 of the 48 receptors and 48 of the  
192 240 pairings in our sample (Fig 3; S1 File). We detected constitutive coupling of 18 receptors to  
193  $G_{i1}$ , 8 receptors to  $G_s$ , 6 receptors to  $G_q$ , 7 receptors to  $G_{13}$ , and 9 receptors to  $G_{15}$ . Of the 22  
194 profiled receptors 11 are annotated for G protein coupling in the IUPHAR Guide to  
195 Pharmacology (GtoPdb), and within this set there was excellent agreement between our results  
196 and annotated coupling [13] (S1 File). The sole exception was GPR75, which coupled to  $G_{i1}$  in  
197 our dataset but is annotated as coupling to  $G_q$ . This receptor has been shown to stimulate  
198 inositol phosphate turnover and calcium release in other studies [25]. In several cases, our  
199 results agreed with annotated receptor-G protein pairs, but also indicated coupling to additional  
200 G protein families. For example, our results confirmed coupling of GPR26 to  $G_s$  [26], but  
201 indicated additional coupling to  $G_{i1}$ ,  $G_{15}$  and  $G_q$ . We also found several instances where no G  
202 protein coupling was annotated in GtoPdb, but where published reports indicated signaling  
203 through a particular G protein pathway. In such cases our results were also generally in good  
204 agreement with previous reports, but again indicated coupling to additional G proteins that was  
205 previously unreported. For example, GPR62 has been shown to constitutively activate adenylyl  
206 cyclase (AC), albeit weakly, suggesting coupling to  $G_s$  [27]. Our results confirm that this receptor  
207 couples to  $G_s$ , but also show similar coupling to  $G_{i1}$  and  $G_{15}$ . Dual coupling to  $G_i$  and  $G_s$  proteins  
208 may help to explain relatively weak constitutive activation of AC by this receptor. These results  
209 illustrate the value of an unbiased profiling approach that includes G proteins from all four  $G\alpha$   
210 subunit families.

211  
212 For 26 of the receptors we studied  $\Delta\text{BRET}_{\text{GDP}}$  did not meet threshold for any of the G proteins  
213 tested. The most likely explanation for this outcome is that these receptors simply lacked  
214 sufficient constitutive activity to couple efficiently to G proteins in the absence of a ligand.  
215 However, one alternative explanation is the failure of these receptors to traffic efficiently to the  
216 plasma membrane, where the majority of G protein heterotrimers are located. To test this idea  
217 we measured bystander BRET between each receptor and markers of the plasma membrane



218 (PM) and endoplasmic reticulum (ER) [18]. Most receptors showed substantial BRET to the PM  
219 marker, and less BRET to the ER marker, indicating efficient trafficking to the cell surface.  
220 However, 8 receptors (GPR31, GPR37L1, GPR142, GPR146, GPR148, GPR152, GPR160 and  
221 MRGPRG) showed BRET to the ER marker that exceeded BRET to the PM marker, indicating  
222 inefficient trafficking to the PM (S1 File). All 8 of these receptors were among the 26 that failed  
223 to show constitutive G protein coupling, suggesting that retention of these receptors in the  
224 biosynthetic pathway may have contributed to our inability to detect G protein coupling.

225

### 226 **Receptor-arrestin interactions**

227 It is also possible that some of the receptors that we studied do not couple to G proteins at all,  
228 as is the case for some “decoy” receptors (e.g. the C5a2 complement receptor) [28]. Because  
229 some decoy receptors bind to  $\beta$ -arrestins we asked if any of the orphan receptors in our sample  
230 interacted constitutively with these transducers by measuring basal BRET between receptors  
231 and Venus- $\beta$ -arrestin-1 and Venus- $\beta$ -arrestin-2 in intact cells. Basal BRET between  
232 unstimulated GPCRs and arrestins is typically low unless there is a specific interaction [29], or  
233 unless arrestins are recruited in some other way to membrane compartments where receptors  
234 are located. Accordingly, basal BRET between orphan receptors and Venus- $\beta$ -arrestins was low  
235 for most of the receptors in our sample (Fig 3; S1 File). However, GPR182 and GPR4 were both  
236 outliers for both  $\beta$ -arrestin-1 and  $\beta$ -arrestin-2. GPR182 failed to couple detectably to G proteins,  
237 suggesting that this receptor may be biased towards interacting with arrestins rather than G  
238 proteins.

239

## 240 Discussion

241 In the present study we measured guanine nucleotide-sensitive coupling of G proteins to a  
242 sample of understudied orphan GPCRs. We used an unbiased approach that directly indicates  
243 receptor association with unmodified  $G\alpha$  subunits and does not require an activating ligand. We  
244 were able to detect G protein coupling to 22 of the 48 receptors we studied. We confirmed many  
245 receptor-G protein pairings determined previously by other methods, and demonstrated several  
246 new pairings. With respect to the overall prevalence of coupling to different G protein subtypes,  
247 our results with constitutive activity of orphan receptors agree well with previous studies of  
248 agonist-induced coupling of non-orphan GPCRs [9–12].  $G_{i1}$  was the most frequent coupler (18  
249 receptors), whereas the  $G_{q/11}$  family (including  $G_q$  and  $G_{15}$ ) was the second-most frequent (15  
250 receptors). Of the 9 receptors that coupled to only one G protein, 7 coupled solely to  $G_{i1}$ . We  
251 also found that coupling to  $G_{13}$  (7 receptors) was more common in our dataset than might be  
252 predicted based on GtoPdb annotations of all GPCRs, as shown previously by others [9,10]. It is  
253 possible that coupling to  $G_{12/13}$  is underrepresented in GtoPdb because simple second  
254 messenger assays are not available for this family. Coupling to  $G_{13}$  was always observed in  
255 conjunction with coupling to another G protein [30]. Among the  $G_{13}$ -coupled receptors in our  
256 sample were all 4 members of a closely-related family of acid-sensing receptors (GPR4,  
257 GPR65, GPR68 and GPR132) [31], all of which coupled to  $G_{13}$  at least as well as any other G  
258 protein.

259  
260 The assay that we used here has a particular advantage for studies of constitutive receptor  
261 activity, in that GDP can essentially be used as a common ligand to disrupt coupled GPCR-G  
262 protein complexes. This comes with a significant drawback, in that constitutive activity is  
263 required, and a subjective threshold was needed to assign receptor-G protein coupling. It is  
264 likely that many of the receptors that we were unable to profile will couple well to G proteins  
265 when bound to an activating ligand. Although these caveats mean that our study undoubtedly  
266 missed several receptor-G protein pairings, it also suggests that our results can help predict  
267 which of these orphan receptors have high and low constitutive activity. For example, GPR18 is  
268 a relatively well-studied receptor (Jensen PubMed Score 42.64) that binds to endogenous  
269 cannabinoid compounds [32] and is annotated in GtoPdb as coupling to  $G_{i/o}$  and  $G_{q/11}$ . This  
270 receptor showed subthreshold  $\Delta BRET_{GDP}$  (which was greatest for  $G_{i1}$ ) in our study, suggesting  
271 that GPR18 has low constitutive activity compared to other receptors in our sample. Another  
272 limitation of our study is that we did not address selectivity among G proteins within a family,  
273 although this could be easily rectified with additional studies. We also identified several orphan

274 receptors that are at least partly retained in the endoplasmic reticulum of HEK 293 cells. These  
275 receptors may require cell type-specific trafficking factors to reach the plasma membrane. For  
276 example, GPR37L1 is expressed almost exclusively in glial cells and is thought to couple to G<sub>i/o</sub>  
277 proteins [33], but trafficked poorly to the cell surface in HEK 293 cells.

278

279 We found one receptor, GPR182, that did not couple to G proteins in our assay, but did  
280 constitutively interact with  $\beta$ -arrestins. This result is consistent with a previous study that  
281 showed very high constitutive binding of a GPR182-V2R vasopressin receptor fusion protein to  
282  $\beta$ -arrestin [16]. Gene-transcription studies suggest that this receptor may also signal through  
283 several canonical G protein pathways [34], but specific G protein coupling has not been  
284 reported. Given the demonstrated importance of GPR182 for cellular proliferation and  
285 hematopoiesis [35,36], our results suggest that further studies of GPR182 signaling  
286 mechanisms are warranted.

287

288 In summary, we were able to profile constitutive G protein coupling for a significant fraction of  
289 understudied class A orphan GPCRs. The success of this strategy suggests that it may be  
290 useful for profiling G protein coupling of other GPCRs (e.g. adhesion receptors and class C  
291 orphans) for which well-validated activating ligands are not available.

292

293

294 **Acknowledgements:** We thank Steve Ikeda, Seva Gurevich, Kirill Martemyanov and Bryan  
295 Roth for providing plasmid DNA used in this study. This work was supported by a grant from the  
296 National Institutes of Health (GM130142 to N.A.L.). A.I. was funded by the PRIME  
297 JP19gm5910013, the LEAP JP19gm0010004 and the BIND JP19am0101095 from the Japan  
298 Agency for Medical Research and Development (AMED).


299

300 **References:**

- 301 1. Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR  
302 drug discovery: New agents, targets and indications. *Nat Rev Drug Discov.* 2017;16:  
303 829–842. doi:10.1038/nrd.2017.178
- 304 2. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. *Nat Rev Mol*  
305 *Cell Biol.* 2002;3: 639–650.
- 306 3. Milligan G. Principles: Extending the utility of [35S]GTPγS binding assays. *Trends in*  
307 *Pharmacological Sciences.* *Trends Pharmacol Sci*; 2003. pp. 87–90. doi:10.1016/S0165-  
308 6147(02)00027-5
- 309 4. Hollins B, Kuravi S, Digby GJ, Lambert NA. The c-terminus of GRK3 indicates rapid  
310 dissociation of G protein heterotrimers. *Cell Signal.* 2009;21: 1015–1021. Available:  
311 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19258039)  
312 [&list\\_uids=19258039](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19258039)
- 313 5. Galés C, Van Durm JJJ, Schaak S, Pontier S, Percherancier Y, Audet M, et al. Probing  
314 the activation-promoted structural rearrangements in preassembled receptor–G protein  
315 complexes. *Nat Struct Mol Biol.* 2006;13: 778–786. doi:10.1038/nsmb1134
- 316 6. Gales C, Rebois R V, Hogue M, Trieu P, Breit A, Hebert TE, et al. Real-time monitoring of  
317 receptor and G-protein interactions in living cells. *Nat Methods.* 2005;2: 177–184.  
318 Available:  
319 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15782186)  
320 [&list\\_uids=15782186](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15782186)
- 321 7. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, et al. TGFα shedding  
322 assay: An accurate and versatile method for detecting GPCR activation. *Nat Methods.*  
323 2012;9: 1021–1029. doi:10.1038/nmeth.2172
- 324 8. Wan Q, Okashah N, Inoue A, Nehmé R, Carpenter B, Tate CG, et al. Mini G protein  
325 probes for active G protein–coupled receptors (GPCRs) in live cells. *J Biol Chem.*  
326 2018;293: 7466–7473. doi:10.1074/jbc.RA118.001975
- 327 9. Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, et al. Illuminating G-  
328 Protein-Coupling Selectivity of GPCRs. *Cell.* 2019;177: 1933-1947.e25.  
329 doi:10.1016/j.cell.2019.04.044
- 330 10. Avet C, Mancini A, Breton B, Gouill C Le, Hauser AS, Normand C, et al. Selectivity  
331 Landscape of 100 Therapeutically Relevant GPCR Profiled by an Effector Translocation-  
332 Based BRET Platform. *bioRxiv.* 2020; 2020.04.20.052027.  
333 doi:10.1101/2020.04.20.052027
- 334 11. Masuho I, Ostrovskaya O, Kramer GM, Jones CD, Xie K, Martemyanov KA. Distinct  
335 profiles of functional discrimination among G proteins determine the actions of G protein-  
336 coupled receptors. *Sci Signal.* 2015;8: ra123–ra123. doi:10.1126/scisignal.aab4068
- 337 12. Kapolka NJ, Taghon GJ, Rowe JB, Morgan WM, Enten JF, Lambert NA, et al. Dcyfir: A  
338 high-throughput CRISPR platform for multiplexed G protein-coupled receptor profiling and  
339 ligand discovery. *Proc Natl Acad Sci U S A.* 2020;117: 13117–13126.  
340 doi:10.1073/pnas.2000430117
- 341 13. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, et al. THE  
342 CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. *Br J*  
343 *Pharmacol.* 2019;176: S21–S141. doi:10.1111/bph.14748
- 344 14. Okashah N, Wan Q, Ghosh S, Sandhu M, Inoue A, Vaidehi N, et al. Variable G protein  
345 determinants of GPCR coupling selectivity. *Proc Natl Acad Sci U S A.* 2019;116: 12054–  
346 12059. doi:10.1073/pnas.1905993116
- 347 15. Seifert R, Wenzel-Seifert K. Constitutive activity of G-proteins-coupled receptors: Cause  
348 of disease and common property of wild-type receptors. *Naunyn-Schmiedeberg's*  
349 *Archives of Pharmacology.* *Naunyn Schmiedebergs Arch Pharmacol*; 2002. pp. 381–416.  
350 doi:10.1007/s00210-002-0588-0

- 351 16. Kroeze WK, Sassano MF, Huang X-P, Lansu K, McCorvy JD, Giguère PM, et al.  
352 PRESTO-Tango as an open-source resource for interrogation of the druggable human  
353 GPCRome. *Nat Struct Mol Biol.* 2015;22: 362–9. doi:10.1038/nsmb.3014
- 354 17. Stoveken HM, Zucca S, Masuho I, Grill B, Martemyanov KA. The orphan receptor  
355 GPR139 signals via Gq/11 to oppose opioid effects. *J Biol Chem.* 2020;295.  
356 doi:10.1074/jbc.ac120.014770
- 357 18. Lan T-H, Liu Q, Li C, Wu G, Lambert NA. Sensitive and High Resolution Localization and  
358 Tracking of Membrane Proteins in Live Cells with BRET. *Traffic.* 2012;13.  
359 doi:10.1111/j.1600-0854.2012.01401.x
- 360 19. Grundmann M, Merten N, Malfacini D, Inoue A, Preis P, Simon K, et al. Lack of beta-  
361 arrestin signaling in the absence of active G proteins. *Nat Commun.* 2018;9: 341.  
362 doi:10.1038/s41467-017-02661-3
- 363 20. Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression - A  
364 new method based on robust nonlinear regression and the false discovery rate. *BMC*  
365 *Bioinformatics.* 2006;7: 123. doi:10.1186/1471-2105-7-123
- 366 21. Sheils TK, Mathias SL, Kelleher KJ, Siramshetty VB, Nguyen D-T, Bologna CG, et al.  
367 TCRD and Pharos 2021: mining the human proteome for disease biology. *Nucleic Acids*  
368 *Res.* 2021;49: D1334–D1346. doi:10.1093/nar/gkaa993
- 369 22. Rodgers G, Austin C, Anderson J, Pawlyk A, Colvis C, Margolis R, et al. Glimmers in  
370 illuminating the druggable genome. *Nature Reviews Drug Discovery.* Nature Publishing  
371 Group; 2018. pp. 301–302. doi:10.1038/nrd.2017.252
- 372 23. Offermanns S, Simon MI. Gα15 and gα16 couple a wide variety of receptors to  
373 phospholipase C. *J Biol Chem.* 1995;270: 15175–15180. doi:10.1074/jbc.270.25.15175
- 374 24. Zhao R, Chen X, Ma W, Zhang J, Guo J, Zhong X, et al. A GPR174–CCL21 module  
375 imparts sexual dimorphism to humoral immunity. *Nature.* 2020;577: 416–420.  
376 doi:10.1038/s41586-019-1873-0
- 377 25. Ignatov A, Robert J, Gregory-Evans C, Schaller HC. RANTES stimulates Ca<sup>2+</sup>  
378 mobilization and inositol trisphosphate (IP<sub>3</sub>) formation in cells transfected with G protein-  
379 coupled receptor 75. *Br J Pharmacol.* 2006;149: 490–497. doi:10.1038/sj.bjp.0706909
- 380 26. Jones PG, Nawoschik SP, Sreekumar K, Uveges AJ, Tseng E, Zhang L, et al. Tissue  
381 distribution and functional analyses of the constitutively active orphan G protein coupled  
382 receptors, GPR26 and GPR78. *Biochim Biophys Acta.* 2007;1770: 890–901.  
383 doi:10.1016/j.bbagen.2007.01.013
- 384 27. Oishi A, Karamitri A, Gerbier R, Lahuna O, Ahmad R, Jockers R. Orphan GPR61, GPR62  
385 and GPR135 receptors and the melatonin MT<sub>2</sub> receptor reciprocally modulate their  
386 signaling functions. *Sci Rep.* 2017;7. doi:10.1038/s41598-017-08996-7
- 387 28. Li XX, Lee JD, Kemper C, Woodruff TM. The Complement Receptor C5aR2: A Powerful  
388 Modulator of Innate and Adaptive Immunity. *J Immunol.* 2019;202: 3339–3348.  
389 doi:10.4049/jimmunol.1900371
- 390 29. Angers S, Salahpour A, Joly E, Hilaiet S, Chelsky D, Dennis M, et al. Detection of beta  
391 2-adrenergic receptor dimerization in living cells using bioluminescence resonance  
392 energy transfer (BRET). *Proc Natl Acad Sci U S A.* 2000;97: 3684–3689. Available:  
393 [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10725388)  
394 [&list\\_uids=10725388](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10725388)
- 395 30. Riobo NA, Manning DR. Receptors coupled to heterotrimeric G proteins of the G12  
396 family. *Trends Pharmacol Sci.* 2005;26: 146–154. doi:10.1016/j.tips.2005.01.007
- 397 31. Tomura H, Mogi C, Sato K, Okajima F. Proton-sensing and lysolipid-sensitive G-protein-  
398 coupled receptors: A novel type of multi-functional receptors. *Cellular Signalling. Cell*  
399 *Signal;* 2005. pp. 1466–1476. doi:10.1016/j.cellsig.2005.06.002
- 400 32. Irving A, Abdulrazzaq G, Chan SLF, Penman J, Harvey J, Alexander SPH. Cannabinoid  
401 Receptor-Related Orphan G Protein-Coupled Receptors. *Advances in Pharmacology.*


- 402 Academic Press Inc.; 2017. pp. 223–247. doi:10.1016/bs.apha.2017.04.004  
403 33. Meyer RC, Giddens MM, Schaefer SA, Hall RA. GPR37 and GPR37L1 are receptors for  
404 the neuroprotective and glioprotective factors prosaptide and prosaposin. *Proc Natl Acad*  
405 *Sci U S A*. 2013;110: 9529–9534. doi:10.1073/pnas.1219004110  
406 34. Schmid CD, Schledzewski K, Mogler C, Waldburger N, Kalna V, Marx A, et al. GPR182 is  
407 a novel marker for sinusoidal endothelial differentiation with distinct GPCR signaling  
408 activity in vitro. *Biochem Biophys Res Commun*. 2018;497: 32–38.  
409 doi:10.1016/j.bbrc.2018.01.185  
410 35. Kechele DO, Blue RE, Zwarycz B, Espenschied ST, Mah AT, Siegel MB, et al. Orphan  
411 Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and  
412 adenoma formation. *J Clin Invest*. 2017;127: 593–607. doi:10.1172/JCI87588  
413 36. Kwon HB, Mackie DI, Bonnavion R, Mercier A Le, Helker CSM, Son T, et al. The Orphan  
414 G-Protein Coupled Receptor 182 Is a Negative Regulator of Definitive Hematopoiesis  
415 through Leukotriene B4 Signaling. *ACS Pharmacol Transl Sci*. 2020;3: 676–689.  
416 doi:10.1021/acscptsci.0c00020  
417  
418



419

420 **Fig 1. Addition of GDP disrupts GPCR-G protein complexes.** (A) Cartoon representation of  
421 the experimental design. Constitutively-active GPCRs fused to *Renilla* luciferase (Rluc8) form  
422 spontaneous active-state complexes with nucleotide-free G protein heterotrimers fused (via the  
423 G $\beta\gamma$  subunit) to the fluorescent protein Venus in the absence of activating ligands. Addition of  
424 GDP (100  $\mu$ M) disrupts these complexes, decreasing BRET between GPCR-Rluc8 and G $\alpha\beta\gamma$ -  
425 Venus. (B) Representative experiments of this type with GPR82 and GPR174. Traces represent  
426 the mean  $\pm$  SD of 16 technical replicates from a single experiment, and each trace is normalized  
427 to the basal BRET observed for that particular G protein. GDP was injected where indicated by  
428 the horizontal bar.

429




430

431 **Fig 2. Determination of threshold  $\Delta\text{BRET}_{\text{GDP}}$ .** Most receptor-G protein pairs did not interact,  
432 and values of  $\Delta\text{BRET}_{\text{GDP}}$  were distributed around zero. Values below the dashed horizontal line  
433 ( $\Delta\text{BRET}_{\text{GDP}} = -0.009$ ) were identified as outliers from this background distribution (i.e. coupled  
434 pairs) with a false discovery rate (FDR) of 1%. Each point represents a single receptor-G protein  
435 pair, and the mean of three independent experiments performed in duplicate.

436





437  
 438 **Fig 3. Constitutive G protein and  $\beta$ -arrestin coupling of understudied GPCRs.** Heat maps  
 439 representing the mean  $\Delta BRET_{GDP}$  for 200 receptor-G protein pairs (blue) and basal net BRET  
 440 for 80 receptor- $\beta$ -arrestin pairs (red). The righthand column indicates the G proteins for which  
 441  $\Delta BRET_{GDP}$  exceeded the determined threshold. Each cell represents the mean of three  
 442 independent experiments performed in duplicate. Eight receptors that trafficked poorly to the  
 443 plasma membrane are not shown here.